TY - JOUR
T1 - Dihomo-gamma-linolenic acid levels and obesity in patients with type 2 diabetes
AU - Yamashita, Kaoru
AU - Higa, Mariko
AU - Kunishita, Rieko
AU - Kanazawa, Ken
AU - Tasaki, Mai
AU - Doi, Ayano
AU - Yoshifuji, Ayumi
AU - Ichijo, Takamasa
AU - Ouchi, Hiromi
AU - Hirose, Takahisa
N1 - Publisher Copyright:
© 2014, The Japan Diabetes Society.
PY - 2015/9/4
Y1 - 2015/9/4
N2 - Introduction: We examined the correlation between blood levels of dihomo-gamma-linolenic acid (DGLA), which belongs to the n-6 polyunsaturated fatty acids (PUFAs), and obesity in type 2 diabetic patients. Subjects and Methods: The subjects were 62 type 2 diabetic patients (age 63.3 ± 9.3 years; 35 males and 27 females) who were not taking eicosapentaenoic acid (EPA) agents and were divided into two groups, i.e., an obese group (n = 29) with BMIs >25 kg/m2 and non-obese group (n = 33) with BMIs <25 kg/m2. For the blood PUFA, we measured DGLA, arachidonic acid (AA), EPA and docosahexaenoic acid (DHA) and compared them between the two groups. Results: The blood DGLA level was found to be significantly (p < 0.01) higher in the obese group (39.2 ± 12.0 μg/ml) than in the non-obese group (32.1 ± 9.5 μg/ml). The DGLA/AA ratio was also significantly (p < 0.01) higher in the obese group (0.24 ± 0.09) than in the non-obese group (0.19 ± 0.06). However, no significant differences were found in the blood levels of the AA, EPA, DHA or EPA/AA ratios between the two groups. The blood DGLA level showed a significant, positive correlation with BMI (r = 0.367, p < 0.01), waist circumference (r = 0.336, p < 0.01), AST (r = 0.262, p < 0.05), ALT (r = 0.291, p < 0.05), blood triglyceride (r = 0.439, p < 0.0001) and leptin level (r = 0.464, p < 0.001), respectively. Conclusion: These results suggest that high levels of blood DGLA in type 2 diabetic patients with obesity may be attributable to an excessive intake of n-6-PUFA and the decrease in desaturase activity converting DGLA to AA.
AB - Introduction: We examined the correlation between blood levels of dihomo-gamma-linolenic acid (DGLA), which belongs to the n-6 polyunsaturated fatty acids (PUFAs), and obesity in type 2 diabetic patients. Subjects and Methods: The subjects were 62 type 2 diabetic patients (age 63.3 ± 9.3 years; 35 males and 27 females) who were not taking eicosapentaenoic acid (EPA) agents and were divided into two groups, i.e., an obese group (n = 29) with BMIs >25 kg/m2 and non-obese group (n = 33) with BMIs <25 kg/m2. For the blood PUFA, we measured DGLA, arachidonic acid (AA), EPA and docosahexaenoic acid (DHA) and compared them between the two groups. Results: The blood DGLA level was found to be significantly (p < 0.01) higher in the obese group (39.2 ± 12.0 μg/ml) than in the non-obese group (32.1 ± 9.5 μg/ml). The DGLA/AA ratio was also significantly (p < 0.01) higher in the obese group (0.24 ± 0.09) than in the non-obese group (0.19 ± 0.06). However, no significant differences were found in the blood levels of the AA, EPA, DHA or EPA/AA ratios between the two groups. The blood DGLA level showed a significant, positive correlation with BMI (r = 0.367, p < 0.01), waist circumference (r = 0.336, p < 0.01), AST (r = 0.262, p < 0.05), ALT (r = 0.291, p < 0.05), blood triglyceride (r = 0.439, p < 0.0001) and leptin level (r = 0.464, p < 0.001), respectively. Conclusion: These results suggest that high levels of blood DGLA in type 2 diabetic patients with obesity may be attributable to an excessive intake of n-6-PUFA and the decrease in desaturase activity converting DGLA to AA.
KW - Dihomo-gamma-linolenic acid (DGLA)
KW - Obesity
KW - Polyunsaturated fatty acids (PUFA)
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84940765253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940765253&partnerID=8YFLogxK
U2 - 10.1007/s13340-014-0187-6
DO - 10.1007/s13340-014-0187-6
M3 - Article
AN - SCOPUS:84940765253
VL - 6
SP - 206
EP - 211
JO - Diabetology International
JF - Diabetology International
SN - 2190-1678
IS - 3
ER -
